Trials / Completed
CompletedNCT03304522
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy of VX-150 for the treatment of pain caused by small fiber neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-150 | Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks. |
| DRUG | Placebo | Participants received placebo matched to VX-150 for 6 weeks. |
Timeline
- Start date
- 2017-09-20
- Primary completion
- 2018-10-12
- Completion
- 2018-11-08
- First posted
- 2017-10-09
- Last updated
- 2021-11-15
- Results posted
- 2021-11-15
Locations
34 sites across 4 countries: United States, Germany, Italy, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03304522. Inclusion in this directory is not an endorsement.